Navigation Links
Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
Date:6/12/2013

NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that preclinical studies have shown that combining the galectin inhibitor GR-MD-02 with monoclonal antibodies that function as immune checkpoint blockade inhibitors enhance shrinkage of prostate and breast cancer tumors. These data were generated by the laboratory of Dr. William Redmond of the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute (EACRI) at Providence Cancer Center (Portland, OR), an expert in tumor immunology and part of a comprehensive pre-clinical and clinical program in cancer immunotherapy. The addition of GR-MD-02, a drug that inhibits galectin proteins, was found to increase tumor shrinkage and enhance survival in immune competent mice with prostate and breast cancers when combined with one of the immune checkpoint blockade inhibitors, anti-CTLA-4 or anti-PD-1.

"Immunotherapy with checkpoint blockade inhibitors, such as anti-CTLA-4 monoclonal antibodies (marketed as YERVOY™ by Bristol-Myers Squibb (BMS)) and anti-PD-1 monoclonal antibodies (in development at BMS and Merck), is an extremely exciting area for advancing human cancer immunotherapy," said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. "However, these agents are currently only effective in a limited percentage of patients. The ability of GR-MD-02 to increase the effectiveness of these important drugs is a potentially important approach to enhance cancer immunotherapy."

"The findings of these experiments show that GR-MD-02 had a robust effect on augmenting the immune response and tum
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
8. ClearCanvas Platform Powers Tumor Imaging Metrics Core Measurements
9. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
10. Lo screening trial sul cancro al seno conclude che lutilizzo della mammografia 3D in combinazione con un esame del seno 2D rileva un numero di tumori significativamente maggiore rispetto al solo esame del seno 2D
11. La nuova tecnologia Elekta per la radioterapia oncologica ridefinirà il futuro della lotta contro i tumori
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/18/2014)... 21, 2014) -- A group of scientists from ... the Sanders-Brown Center on Aging has found interesting ... neuropsychological function in Parkinson,s disease (PD). , ... the study, which assessed cognitive function in depressed ... dopamine replacement therapy commonly used to treat motor ...
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Oct. 27 Inspired by recent breakthroughs in research, today ... initiative entitled Research to Reality: Funding Progress. ... progress of crucial research, and bring promise to reality. ... battle with Rett syndrome in 2003 at age 16, will ...
... 2009 A diverse group of health care ... week that are designed to promote better medication ... The group, which includes the American College of ... Stores, the National Consumers League and the Pharmaceutical ...
... the world use medicines based on statins to lower their ... published in the prestigious journal PNAS, shows that statins may ... Statins lower cholesterol by blocking certain enzymes involved in our ... important lipids in the body, such as the lipids that ...
... developing a range of miniaturised wearable and track-side sensors, ... British athletes improve their performance on the world stage, ... will be officially launched tomorrow (28 October 2009). ... Sensing (ESPRIT) project is funded by the EPSRC and ...
... lead and some had known skin allergens , TUESDAY, Oct. ... are set to paint their faces this Halloween to look ... according to a new report released just in time for ... Safe Cosmetics, is titled: Pretty Scary: Could Halloween Face ...
... 27 Polar ( www.polarusa.com ), the leader in ... technology today introduced two new training computers designed to ... clear guidance, feedback and easy-to-use features including heart rate, which can ... person is using a heart rate monitor for the first time ...
Cached Medicine News:Health News:IRSF Receives 1 Million Dollar Matching Gift 2Health News:IRSF Receives 1 Million Dollar Matching Gift 3Health News:IRSF Receives 1 Million Dollar Matching Gift 4Health News:Experts offer policy recommendations for improving medication adherence 2Health News:Experts offer policy recommendations for improving medication adherence 3Health News:Major research collaboration will improve British athletes' performance on world stage 2Health News:Major research collaboration will improve British athletes' performance on world stage 3Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 2Health News:Two New Easy-To-Use Training Computers from Polar Simplify the Benefits of Exercising with Heart Rate 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: